Skip to main content
. 2023 Mar 30;17(3):e0011236. doi: 10.1371/journal.pntd.0011236

Fig 5. Fold change from baseline in anti-Sm-TSP-2 IgG levels at study day 127 by vaccine group.

Fig 5

Per-protocol immunogenicity population. Vaccinations were administered on study days 1, 57, and 113. Error bars represent 95% confidence intervals. Euvax B hepatitis B recipients were pooled across cohorts.